Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pramana GLP-1 receptor agonist (small molecule)
- Development stage
- Preclinical
- Lead developer
- Pramana Pharmaceuticals
- Modality
- Small Molecules
01
Overview
Pramana Pharmaceuticals is developing a novel small-molecule Glucagon-like peptide 1 receptor (GLP-1R) agonist as part of its "next-generation" GLP-1 pipeline. Unlike traditional peptide-based GLP-1 therapies that require injection, this asset is a small molecule designed for oral potential and targeted cardiometabolic and hepatic health. The program is currently in the IND-enabling stage for a cluster of indications including pancreatitis, cholestasis, primary biliary cholangitis (PBC), and chronic kidney disease (CKD). By activating the GLP-1 receptor, the drug aims to leverage the metabolic and anti-inflammatory effects of GLP-1 signaling to treat renal and hepatic disorders.
02
Targets
Beyond the preview
Go deeper on Pramana GLP-1 receptor agonist (small molecule).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pramana GLP-1 receptor agonist (small molecule).